This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LEVY, F. Articles by FISCHER, J. A. Search for Related Content PubMed PubMed Citation Articles by LEVY, F. Articles by FISCHER, J. A.

Formation of Neutralizing Antibodies During Intranasal Synthetic Salmon Calcitonin Treatment of Paget's Disease^*

Research Laboratory for Calcium Metabolism, Departments of Orthopedic Surgery and Medicine, University of Zurich 8008 Zurich, Switzerland

Address all correspondence and requests for reprints to: Dr. J. A. Fischer, Klinik Balgrist, Forchstrasse 340, 8008 Zurich, Switzerland.

Nine patients with Paget's disease were treated with 200 U (15 nmol) synthetic salmon calcitonin (sCT) intra-nasally (in)/day for 12 months. Five of them had received im or i n sCT therapy for 1–4 yr up to 0.5–5 yr before this study. Low titer antibodies to sCT were detected in the serum of three of these five patients, but not in the four patients who had not received prior sCT therapy. After 2 months of in sCT administration, four of the former group, but none of the latter group, had antibodies to sCT. After 12 months of treatment, antibodies to sCT were found in all patients who had received sCT earlier and in three of the four patients who had not. The half-maximal inhibition of [¹²⁵I]sCT binding ranged from 44-284 pmol/L sCT. In a cultured human breast cancer cell line (T47D) cAMP production was stimulated by sCT (EC₅₀, 70 pmol/L). cAMP production stimulated by sCT (5 pmol/L) was reduced to 6–20% of the control value in the presence of serum from patients which inhibited [¹²⁵I]sCT binding by more than 50% in a dilution of 1:50 or greater. In patients with lower titer antibodies cAMP production was not inhibited. Serum alkaline phosphatase activity was transiently lowered to 79 ± 6% (±SE) of basal levels in the patients who had earlier received sCT (P > 0.1), while sustained reduction to between 66 ± 2% and 84 ± 6% of basal levels (P < 0.05) occurred in the patients who had not been treated with sCT previously. In conclusion, reexposure to sCT of five patients with Paget's disease caused secondary antibody responses and clinical resistance.

^* This work was supported in part by Grants 3.957-0.84 and 3.823–0.86 from the Swiss National Science Foundation and the Kanton of Zurich.

Received February 11, 1988.

This article has been cited by other articles:

				S. Dasgupta, J. Bayry, S. Andre, J. D. Dimitrov, S. V. Kaveri, and S. Lacroix-Desmazes Auditing Protein Therapeutics Management by Professional APCs: Toward Prevention of Immune Responses against Therapeutic Proteins J. Immunol., August 1, 2008; 181(3): 1609 - 1615. [Abstract] [Full Text] [PDF]

				S. B. Fowler, S. Poon, R. Muff, F. Chiti, C. M. Dobson, and J. Zurdo Rational design of aggregation-resistant bioactive peptides: Reengineering human calcitonin PNAS, July 19, 2005; 102(29): 10105 - 10110. [Abstract] [Full Text] [PDF]

				G. Andreotti and A. Motta Modulating Calcitonin Fibrillogenesis: AN ANTIPARALLEL {alpha}-HELICAL DIMER INHIBITS FIBRILLATION OF SALMON CALCITONIN J. Biol. Chem., February 20, 2004; 279(8): 6364 - 6370. [Abstract] [Full Text] [PDF]